PUT - SPRINTER OPEN END - NOVO-NORDISK B | Delayed Deutsche Boerse AG 11:12:13 02/07/2024 pm IST | ||
| 0.74 EUR | +48.00% |
|
| Current month | -20.63% | ||
| 1 month | -70.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 02/24/02 | 0.74 | +48.00% |
| 01/24/01 | 0.5 | -20.63% |
| 28/24/28 | 0.63 | +8.62% |
| 27/24/27 | 0.58 | -7.94% |
| 26/24/26 | 0.63 | +65.79% |
Delayed Quote Deutsche Boerse AG
Last update July 02, 2024 at 11:12 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD0KLC |
| ISIN | DE000VD0KLC1 |
| Date issued | 19/02/2024 |
| Strike | 1,046 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.75 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.2 € |
|---|---|
| Lowest since issue | 0.32 € |
| Spread | 0.07 € |
| Spread % | 8.43% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,005
DKK
Average target price
952.2
DKK
Spread / Average Target
-5.22%
- Stock Market
- Certificates
- Certificat
